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The severe acute respiratory syndrome coronavirus 2 spike (S) glycoprotein 
facilitates receptor binding to initiate cell entry that is the critical initial step in 
the infection cycle. Due to S glycoprotein's pivotal role, in this review, we 
pointed to show potential functional and structural consequences of S 
glycoprotein and its variants, which has been related to increased viral load in 
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The novel coronavirus outbreak named COVID-19 
was reported for the first time in December 2019 in 
Wuhan, in the Hubei province of China. Due to the 
rapid spread of infections, the World Health 
Organization (WHO) announced COVID-19 as a 
global health emergency and a pandemic on  January 
30, 2020 (1-4). Elderly and people of any age with 
medical problems are at higher risk for severe illness 
with COVID-19 and even death (5). According to 
results findings in China from 81% of patients with 
COVID-19, approximately 80% of deaths happened in 
adults aged 60 and higher, and only one death in teens 
around 19 (6). Animals such as birds and mammals, 
including humans, are the coronavirus's primary 
source; and are transmitted through aerosols or the 
fecal-oral route (7). 
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Animals such as birds and mammals, including 
 
Figure 1. Schematic structure of Coronaviruses. 
 
Figure 2. Structure of coronavirus spikes. S1: receptor-binding subunit, S2: membrane-fusion subunit, (TM): 
transmembrane anchor, (IC): intracellular tail, and the viral envelope. 
 
Figure 3. The virus entry mechanisms and functions. 
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COVID-19 is the seventh member of the family of 
coronaviruses that infect humans, after MERS-CoV 
and SARS-CoV. Generally, coronaviruses in humans 
cause mild respiratory infections similar to those 
seen in the common cold; although, recently some 
coronavirus infections in humans such as the SARS 
(originated from Southern China), MERS (Middle East 
Respiratory Syndrome, Saudi Arabia in 2012), and 
COVID-19 have led to lethal endemics (7). 
Researchers worldwide are studying to identify the 
novel virus, severe acute respiratory syndrome 
coronavirus 2; SARS-CoV-2 (the cause of COVID-19 
disease), to prevent its dissemination and reduce its 
complications. 
Structure of coronavirus: Coronavirus is an 
enveloped spherical or pleomorphic single-stranded 
RNA virus that ranges from 60 to 220 nm in size. It 
belongs to the Orthocoronavirinae subfamily and falls 
into the genus beta-coronavirus. The virus has variable 
G + C contents (~32% - 43%) and about 26.4–31.7 kb 
among all known RNA viruses that encode some 
structural and unstructured proteins. The nucleocapsid 
(N), Membrane (M), Envelop (E), and Spike (S) are 
four main structural proteins for producing a 
structurally complete viral particle (Fig. 1) (7, 8).  
The Nucleocapsid coats the viral RNA genome 
which has a major function in its replication and 
transcription and promotes the virus attachment to 
human cells to produce virus factories (9). The M-
protein is the most abundant glycoprotein in the viral 
surface that has three domains including a short N 
terminal ectodomain, a triple-spanning transmembrane 
domain, and a C-terminal endodomain. E-protein is a 
small membrane protein with approximately 76 to 109 
amino-acid and a minor component of the virus 
particle. Both E and M proteins have essential 
functions such as viral assembly, budding, and virus 
particle replication as well as a crucial role in 
augmenting the immune response against SARS-CoV 
(10, 11). The S-protein is integrated over the virus's 
surface and is responsible for host receptor binding and 
fusion of the viral and host cell membranes (12). 
 
Structural and functional properties of S 
glycoprotein: The spike (S) glycoprotein of the 
coronavirus, located on the virion's outer envelope, is 
a class I viral fusion protein that binds to receptors on 
coronavirus-susceptible cells induces cell fusion (13). 
 
Figure 4. Schematic representation of spike protein. 
 
Table 1: Mutations reported in spike protein S1 domain of SARS-CoV-2. 














The Spike Protein Mutations and its Effect on SARS-CoV-2 Pathogenesis                                                                    Zandi et al. 
Vol 6, No 6, Spring 2021 
151 
It comprises three segments, including a large 
ectodomain, a single-pass transmembrane anchor 
(TM), and a short intracellular tail (IC). The S 
precursor protein of SARS-CoV-2 consisting of 
~1,300 amino acids is proteolytically divided into two 
subunits; S1 (~700 amino acids) and S2 (~600 amino 
acids) (Fig. 2).  
The S1 subunit contains a receptor-binding 
domain (RBD), and the function of S1 is to bind the 
host cell receptors for viral attachment. S2 subunit 
contains a hydrophobic fusion peptide (FP) and two 
heptad repeat (HR) regions that fuse the host and viral 
membranes, allowing viral genomes to enter host cells. 
S1 and S2 share about 70% and 99% identity with that 
of human SARS-CoVs, respectively (14-16). On the 
other hand, for many coronaviruses and even SARS-
CoV-2, S glycoprotein features two distinct protease 
cleavage sites between the S1 and S2 subunits, which 
remain noncovalently bound in the prefusion 
conformation (12, 17). 
 
Role of spike protein in infection: The initial and 
critical stages in the coronavirus infection cycle are 
receptor binding and membrane fusion. S proteins 
cover the surface of SARS-CoV-2. During viral entry, 
S protein mediates attachment of viral particle to 
angiotensin-converting enzyme 2 (ACE2) as a cellular 
receptor. Then, entry of the virus into the host cell is 
promoted by a type 2 TM serine protease (located on 
the host cell membrane). When the virus enters the cell, 
the viral genetic material, a single-stranded RNA, is 
released, and the RNA genome is translated to generate 
poly-proteins. In the next step, the viral RNA genome 
replication and transcription processes occur via 
protein cleavage and assembly of the 
replication/transcription complex (RTC). The viral 
genome is replicated and translated into proteins, 
finally assembled, and packaged in the host cell, then 
viral particles are released out of host cells. In the last 
novel, virions are exported from infected cells that can 
infect other cells. (Fig. 3) (18-20). 
 
Mutations in spike protein: According to the 
mutation on spike glycoprotein of SARS-CoV-2, 
D614G, G476S, and V483A are the main mutations. 
Other mutations with low frequency in SARS-CoV-2 
spike glycoprotein include L5F, R214L, R408I, 
H519Q, and T572I (Table1). The N-Terminal Domain 
(NTD) of the S1 domain harbors L5F and R214L 
mutations while R408I, H519Q, T572I mutations 
occur at the C-Terminal Domain (CTD) of the S1 
domain (Fig. 4) (21). 
In early February 2020, an aspartic acid-to-
glycine substitution at amino acid position 614 
(D614G) in the S gene was observed in Europe. D614G 
mutation as a non-synonymous mutation of spike 
protein became the dominant variant of SARS-CoV-2 
during the COVID-19 pandemic (22). Zhang et al. 
characterized and compared both variants of SD614 and 
SG614; their analysis revealed that retroviruses 
pseudotyped with SG614 are more efficient than those 
with SD614 in infecting hACE2-expressing cells (23).  
Korber et al. showed that D614G could increase 
viral loads in patients with COVID-19 (24). Recently 
in one study, Plante JA et al. reported that SARS-CoV-
2 replication is increased in cell culture by D614G 
through enhances virion infectivity; however, it also 
improves fitness and transmission of SARS-CoV-2 in 
vitro and in vivo (25). According to clinical findings, a 
study showed that there is not a significant relationship 
between D614G mutation and severity and mortality of 
COVID-19 disease (24); however, more research about 
this issue is needed. Hydrophobicity of the SS may 
enhance via L5F as another mutation; it may facilitate 
protein folding and assembly of virion through S 
glycoproteins mediate entry into ER (26). 
The dominant D614G variant has little effect on 
the epitope and its antigenicity. While the epitopes and 
antigenicity of some mutants with a low frequency 
significantly change (27). Because of mutations on S 
glycoprotein, it is considered a key target for SARS-
CoV-2 development vaccines, therapeutic drugs 
against SARS-CoV-2 and can be crucial in diagnostics 
of the virus; among mentioned mutations, D614G and 
L5F are more critical. 
According to WHO reports, different 
vaccine technology platforms are used to develop an 
effective vaccine against COVID-19. As of 02 October 
2020, 42 candidate vaccines are in phase III clinical 
trials evaluation. However, there are also 151 COVID-
19 candidate vaccines in preclinical evaluating. 
Formulation of both clinical and preclinical COVID-
19 candidate vaccines is designed for intramuscular 
administration (28). 
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Some studies showed that S protein-based 
vaccines against SARS-CoV-2 could induce 
significant cellular and humoral immune responses in 
animal models and clinical trials (29). Similarly, 
SARS-CoV, S gene of SARS-CoV-2 considers as a 
critical target for COVID-19 vaccines (30). The 
receptor-binding domain (RBD) of the spike (S) 
protein can elicit neutralizing antibodies and T-cell 
immune responses (31). Ravichandran S et al. reported 
that RBD immunogen induced high antibody titer with 
higher affinity antibodies than other spike antigens 
(32). Immune cells, such as T cells and RBD-specific 
antibodies, were detected in the sera of discharge 
COVID-19 cases (31). Thus, RBD is considered a 





At the moment, the world is amid a COVID-19 
pandemic, the mutation rate of SARS-CoV-2 as an 
RNA virus is high. Studying mutation as the first step 
of SARS-CoV-2 evolution is significant for 
developing effective vaccines. The SARS-CoV-
2 dominant variant in the spike protein “D614G” 
impacts the transmission and infectivity of the virus. 
However, there are some low-frequency mutations in 
spike protein. Nevertheless, more researches are 
needed on the impact of mutations in the SARS-CoV-
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